Jyong Biotech Ltd. (MENS)
| Market Cap | 124.71M -96.2% |
| Revenue (ttm) | n/a |
| Net Income | -4.67M |
| EPS | -0.06 |
| Shares Out | 74.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,253 |
| Open | 1.680 |
| Previous Close | 1.740 |
| Day's Range | 1.680 - 1.680 |
| 52-Week Range | 1.430 - 43.780 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About MENS
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Financial Performance
Financial StatementsNews
Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California
New Taipei City, Taiwan/San Francisco, CA, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to t...
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech Transcript: AGM 2026
MCS-2 is highlighted for its unique action and safety in treating benign prostatic hyperplasia, with the company among the first to secure FDA phase III approval for a botanical drug, positioning it for early market entry.
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
New Taipei City, Taiwan/San Francisco, CA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd.
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
New Taipei City, Taiwan, May 29, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and ...
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and ...
Jyong Biotech Annual report: Q4 2025
Jyong Biotech has published its Q4 2025 annual report on May 15, 2026.
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development an...
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development an...
Jyong issues strategic corporate update, completes Phase II trial for MCS-8
Jyong Biotech (MENS) issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MC...
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value...
Jyong Biotech subsidiary announces phase II data for MCS-8
Jyong Biotech (MENS) announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 conducted in Taiwan. The results underscore MCS-8’s previously i...
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to dev...
Jyong Biotech ‘not aware’ of any material information amid share price movement
Jyong Biotech (MENS) noted the recent fluctuation in its share price and the increased trading volume of its shares on the Nasdaq Stock Exchange following the expiry of the lock-up…
Jyong Biotech Responds to Share Price and Volume Movement
New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”) notes the recent fluctuation in its share price and the increased tradin...
Jyong Biotech Ltd trading resumes
11:25 EST Jyong Biotech (MENS) Ltd trading resumes
Jyong Biotech Ltd trading halted, volatility trading pause
11:15 EST Jyong Biotech (MENS) Ltd trading halted, volatility trading pause
Jyong Biotech signs MOU with Vietnam pharmaceutical distributor
Jyong Biotech (MENS) announced that it has entered into a non-binding Memorandum of Understanding, MOU, with a Vietnam-based pharmaceutical distribution company headquartered in Ho Chi Minh City, to e...
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to dev...
Jyong Biotech signs non-binding LOI with South Korean pharma company
Jyong Biotech (MENS) entered into a non-binding letter of intent with a South Korean pharmaceutical company to review and evaluate the potential in-licensing and development of Jyong Biotech’s plant-d...
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to dev...
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8
Jyong Biotech (MENS) announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8, PCP. The Company has completed the statistical analysis of the primary…
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes
New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to dev...